Immunotherapy for HIV-associated non-Hodgkin's lymphoma

Bibliography

• Ehrlich P. Über den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd 1909;5:273-90
   Google Scholar
• Starnes CO. Coley's toxins in perspective. Nature 1992;357:11-12
   PubMed Web of Science ®Google Scholar
• Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957;18:769-78
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8
   PubMed Web of Science ®Google Scholar
• Van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 1982;79:4718-22
   PubMed Web of Science ®Google Scholar
• Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1:447-56
   PubMed Web of Science ®Google Scholar
• van den Broek ME, Kagi D, Ossendorp F, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996;184:1781-90
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11
   PubMed Web of Science ®Google Scholar
• Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;1:583-7
   PubMed Web of Science ®Google Scholar
• Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995;60:183-9
   PubMed Web of Science ®Google Scholar
• Pham SM, Kormos RL, Landreneau RJ, et al. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 1995;60:1623-6
   PubMed Web of Science ®Google Scholar
• Ziegler JL, Beckstead JA, Volberding PA, et al. Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 1984;311:565-70
   PubMed Web of Science ®Google Scholar
• HIV/AIDS JUNPo: AIDS Epidemic Update. Geneva: UNAIDS; 2007
   Google Scholar
• Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008;198:687-93
   PubMed Web of Science ®Google Scholar
• Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991;337:805-9
   PubMed Web of Science ®Google Scholar
• Biggar RJ, Rosenberg PS, Cote T. Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. Int J Cancer 1996;68:754-8
   PubMed Web of Science ®Google Scholar
• Bower M, Fisher M, Hill T, et al. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica 2009;94:875-80
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol 2008;140:13-24
   PubMed Web of Science ®Google Scholar
• Cote TR, Manns A, Hardy CR, et al. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 1996;88:675-9
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Ambinder RF. AIDS-related primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005;19:665-87, vi-vii
   PubMed Web of Science ®Google Scholar
• MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991;338:969-73
   PubMed Web of Science ®Google Scholar
• Cinque P, Brytting M, Vago L, et al. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet 1993;342:398-401
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60
   PubMed Web of Science ®Google Scholar
• Hammer SM. Increasing choices for HIV therapy. N Engl J Med 2002;346:2022-3
   PubMed Web of Science ®Google Scholar
• Stebbing J, Gazzard B, Mandalia S, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004;22:2177-83
   PubMed Web of Science ®Google Scholar
• Matthews GV, Bower M, Mandalia S, et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000;96:2730-4
   PubMed Web of Science ®Google Scholar
• Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725-30
   PubMed Web of Science ®Google Scholar
• Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1999;21(Suppl 1):S34-41
   PubMed Web of Science ®Google Scholar
• International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92:1823-30
   PubMed Web of Science ®Google Scholar
• Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406-12
   PubMed Web of Science ®Google Scholar
• Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-44
   PubMed Web of Science ®Google Scholar
• Grulich AE, Li Y, McDonald AM, et al. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001;15:629-33
   PubMed Web of Science ®Google Scholar
• Carrieri MP, Pradier C, Piselli P, et al. Reduced incidence of Kaposi's sarcoma and of systemic non-Hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer 2003;103:142-4
   PubMed Web of Science ®Google Scholar
• Franceschi S, Dal Maso L, Pezzotti P, et al. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. J Acquir Immune Defic Syndr 2003;34:84-90
   PubMed Web of Science ®Google Scholar
• Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006;106:128-35
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-54
   PubMed Web of Science ®Google Scholar
• Amyes E, Hatton C, Montamat-Sicotte D, et al. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 2003;198:903-11
   PubMed Web of Science ®Google Scholar
• Ling PD, Vilchez RA, Keitel WA, et al. Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003;37:1244-9
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Milligan DW, Pillay D, et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003;102:839-42
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Wolf E, Fatkenheuer G, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003;17:1521-9
   PubMed Web of Science ®Google Scholar
• Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001;91:155-63
   PubMed Web of Science ®Google Scholar
• Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001;19:2171-8
   PubMed Web of Science ®Google Scholar
• Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001;112:909-15
   PubMed Web of Science ®Google Scholar
• Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002;94:1492-9
   PubMed Web of Science ®Google Scholar
• Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-91
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989;261:719-24
   PubMed Web of Science ®Google Scholar
• Levine AM, Sullivan-Halley J, Pike MC, et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991;68:2466-72
   PubMed Web of Science ®Google Scholar
• Rossi G, Donisi A, Casari S, et al. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer 1999;86:2391-7
   PubMed Web of Science ®Google Scholar
• Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005;143:265-73
   PubMed Web of Science ®Google Scholar
• Zanussi S, Simonelli C, D'Andrea M, et al. The effects of antineoplastic chemotherapy on HIV disease. AIDS Res Hum Retroviruses 1996;12:1703-7
   PubMed Web of Science ®Google Scholar
• Powles T, Imami N, Nelson M, et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002;16:531-6
   PubMed Web of Science ®Google Scholar
• Sparano JA, Wiernik PH, Hu X, et al. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 1998;15:50-7
   PubMed Web of Science ®Google Scholar
• Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004;104:2943-6
   PubMed Web of Science ®Google Scholar
• Ernest CS 2nd, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005;312:583-91
   PubMed Web of Science ®Google Scholar
• Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004;22:2662-70
   PubMed Web of Science ®Google Scholar
• Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653-9
   PubMed Web of Science ®Google Scholar
• Bower M, Powles T, Nelson M, et al. Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst 2006;98:1088-91
   PubMed Web of Science ®Google Scholar
• Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood 1992;80:8-20
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005;105:1891-7
   PubMed Web of Science ®Google Scholar
• Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4123-8
   PubMed Web of Science ®Google Scholar
• Ezzat H, Filipenko D, Vickars L, et al. Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy. HIV Clin Trials 2007;8:132-44
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538-43
   PubMed Web of Science ®Google Scholar
• Koo S, Baden LR. Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy. J Natl Compr Canc Netw 2008;6:202-13
   PubMedGoogle Scholar
• Levine AM, Lee J, Kaplan L, et al. Efficacy and toxicity of concurrent rituximab plus infusional EPOCH in HIV-associated lymphoma: AIDS Malignancy Consortium Trial 034. J Clin Oncol (Meeting Abstracts) 2008;26:8527
   Google Scholar
• Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565-73
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63
   PubMed Web of Science ®Google Scholar
• Maza S, Kiewe P, Munz DL, et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (ZevalinTM) in primary CNS lymphoma. Neuro Oncol 2008 (In Press)
   PubMedGoogle Scholar
• Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336-42
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5
   PubMed Web of Science ®Google Scholar
• Gabarre J, Azar N, Autran B, et al. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 2000;355:1071-2
   PubMed Web of Science ®Google Scholar
• Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005;105:874-8
   PubMed Web of Science ®Google Scholar
• Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008;14:59-66
   PubMed Web of Science ®Google Scholar
• Balsalobre P, Diez-Martin JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009;27:2192-8
   PubMed Web of Science ®Google Scholar
• Diez-Martin JL, Balsalobre P, Re A, et al. Comparable survival between HIV+ and HIV-non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 2009;113:6011-14
   PubMed Web of Science ®Google Scholar
• Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-8
   PubMed Web of Science ®Google Scholar
• Armitage AE, Armitage JD, Armitage JO. Alpha-interferon for relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006;38:701-2
   PubMed Web of Science ®Google Scholar
• Aviles A, Cleto S, Huerta-Guzman J, Neri N. Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens. Eur J Haematol 2001;66:94-9
   PubMed Web of Science ®Google Scholar
• Weiss R, Huhn D, Mitrou P, et al. HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy. Leuk Lymphoma 1998;29:103-18
   PubMed Web of Science ®Google Scholar
• Calabro ML, Gasperini P, Di Gangi IM, et al. Antineoplastic activity of lentiviral vectors expressing interferon-alpha in a preclinical model of primary effusion lymphoma. Blood 2009;113:4525-33
   PubMed Web of Science ®Google Scholar
• Ghosh SK, Wood C, Boise LH, et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood 2003;101:2321-7
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008;27:5932-43
   PubMed Web of Science ®Google Scholar
• Shah MH, Freud AG, Benson DM Jr, et al. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 2006;12:3993-6
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10:281-7
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-26
   PubMed Web of Science ®Google Scholar
• Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96:1921-5
   PubMed Web of Science ®Google Scholar
• Grube M, Moritz S, Obermann EC, et al. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res 2007;13:1053-60
   PubMed Web of Science ®Google Scholar
• Schmidt SM, Schag K, Muller MR, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003;102:571-6
   PubMed Web of Science ®Google Scholar
• Andersen MH, Pedersen LO, Capeller B, et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001;61:5964-8
   PubMed Web of Science ®Google Scholar
• Satoh T, Okamoto I, Miyazaki M, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009;15:3872-80
   PubMed Web of Science ®Google Scholar
• Otto K, Andersen MH, Eggert A, et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005;23:884-9
   PubMed Web of Science ®Google Scholar
• Lu J, Verma SC, Murakami M, et al. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (KSHV) upregulates survivin expression in KSHV-Associated B-lymphoma cells and contributes to their proliferation. J Virol 2009;83:7129-41
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13
   PubMed Web of Science ®Google Scholar
• Wilkie GM, Taylor C, Jones MM, et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases. J Immunother 2004;27:309-16
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007;110:1123-31
   PubMed Web of Science ®Google Scholar
• Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004;103:1632-4
   PubMed Web of Science ®Google Scholar
• Robey RC, Lagos D, Gratrix F, et al. The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens. PLoS One 2009;4:e5890
   PubMedGoogle Scholar
• Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 2004;89:1100-8
   PubMed Web of Science ®Google Scholar
• Re A, Michieli M, Casari S, et al. High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long term results of the GICAT study with analysis of prognostic factors. Blood 2009 (In Press)
   Google Scholar